Boundless Bio, Inc. (BOLD)
| Market Cap | 33.40M -7.0% |
| Revenue (ttm) | n/a |
| Net Income | -55.99M |
| EPS | -2.50 |
| Shares Out | 22.42M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 157,854 |
| Open | 1.560 |
| Previous Close | 1.550 |
| Day's Range | 1.490 - 1.560 |
| 52-Week Range | 0.961 - 1.725 |
| Beta | 0.95 |
| Analysts | Strong Buy |
| Price Target | 4.00 (+167.02%) |
| Earnings Date | May 8, 2026 |
About BOLD
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for BOLD stock is "Strong Buy." The 12-month stock price target is $4.0, which is an increase of 167.02% from the latest price.
News
Boundless Bio reports Q1 EPS (60c), consensus (56c)
“We are encouraged by the progress of the KOMODO-1 trial,” said Zachary Hornby, President and Chief Executive Officer of Boundless Bio (BOLD). “We continue to expand the body of evidence…
Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights
Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940 $93 million in cash provides runway through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, May 08, 2026 (...
Boundless Bio presents preclinical data for BBI-940 therapy at AACR
Boundless Bio (BOLD) presents preclinical data supporting its lead ecDNA-directed therapy, BBI-940, at the American Association for Cancer Research Annual Meeting 2026. Boundless has identified a nove...
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
Findings support the ongoing Phase 1 clinical development of BBI-940, an oral, selective kinesin degrader, as a potential first-in-class therapy for select advanced or metastatic breast cancers Findin...
Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to ...
Boundless Bio Transcript: Leerink Global Healthcare Conference 2026
The company is advancing an oral degrader targeting a novel kinesin critical for ecDNA-driven cancers, with a phase I trial underway in select breast cancer subtypes. Strong preclinical data, a robust financial runway, and a disciplined focus on clinical validation underpin its strategy.
Boundless Bio reports Q4 EPS (58c), consensus (52c)
“With the KOMODO-1 trial of BBI-940 actively enrolling, we are excited to evaluate this potentially first-in-class oral Kinesin degrader in patients with breast cancer who are seeking new treatment op...
Boundless Bio sees cash runway into 2H28
Cash, cash equivalents, and short-term investments totaled $107.6 million as of December 31, 2025. The Company expects its cash to fund operations into the second half of 2028, through the…
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment $108 million in cash provides runway into the second half of 2028, through expected clinical proof-of-concept readout for KOMODO-1...
Boundless Bio to Participate in the Leerink Global Healthcare Conference
SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to ...
Boundless Bio Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Oncogene amplification remains a major unmet need in cancer, addressed by targeting ecDNA biology. The phase 1 trial of BBI-940, an oral degrader of a novel kinesin, is enrolling breast cancer patients, with initial data expected this year and efficacy readouts anticipated in the first half of next year.
Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to p...
Boundless Bio announces FDA accepted IND application of BBI-940
Boundless Bio (BOLD) announced that the U.S. Food and Drug Administration, FDA, has accepted its Investigational New Drug, IND, application for its novel Kinesin oral degrader program, BBI-940. The ac...
Boundless ceases enrollment of Phase 1/2 Potentiate trial of BBI-355, BBI-825
Following a strategic portfolio review, Boundless Bio (BOLD) has elected to cease enrollment of the Phase 1/2 Potentiate trial evaluating the combination of BBI-355, its oral, selective CHK1 inhibitor...
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway
BBI-940 IND accepted; initiation of first-in-human clinical trial on track for the first half of 2026 Portfolio prioritization, including discontinuation of POTENTIATE trial, extends operating runway...
Boundless Bio Transcript: Piper Sandler 37th Annual Healthcare Conference
Focused on ecDNA-driven cancers, the company advances a pipeline of first-in-class molecules, including BBI-940, an oral degrader targeting a novel kinesin with promising preclinical results and a first-in-human study planned for 1H 2026. Academic and pharma interest in ecDNA is accelerating.
Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference
SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Boundless Bio, (Nasdaq: BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to p...
Boundless Bio reports Q3 EPS (62c), consensus (58c)
We are advancing a pipeline rooted in tumor-enabling ecDNA biology to bring forward innovative therapies for patients with oncogene-amplified cancers, said Zachary Hornby, President and Chief Executiv...
Boundless Bio sees cash runway into 1H28
Cash, cash equivalents, and short-term investments totaled $117.6 million as of September 30, 2025.
Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights
Enrollment ongoing in BBI-355 / BBI-825 combination arm of the POTENTIATE trial Investigational new drug submission for BBI-940 on track, with a first-in-human clinical trial expected to initiate in t...
Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Boundless Bio will be presenting upcoming poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Boundless Bio price target lowered to $4 from $5 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Boundless Bio (BOLD) to $4 from $5 and keeps a Buy rating on the shares following the Q2 report. Published first on…
Boundless Bio reports Q2 EPS (70c), consensus (65c)
“We are executing with sharpened focus on programs that we believe have the strongest scientific rationale and greatest potential to impact patients with oncogene-amplified cancers,” said Zachary Horn...
Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights
BBI-355 and BBI-825 combination arm of the POTENTIATE trial is now open for enrollment BBI-940 is on track for submission of an investigational new drug application in the first half of 2026 $127 mill...
Boundless Bio initiated with Early-Stage Biotech at Goldman Sachs
Goldman Sachs analyst Richard Law initiated coverage of Boundless Bio (BOLD) with an Early-Stage Biotech rating, saying the company’s combo approach for its lead asset BBI-355 comes with high risk.